Qt Imaging Holdings, Inc. · NASDAQ:QTI
Qt Imaging — GigCapital5 — SPAC Merger (January 2024)
43 slides from Qt Imaging's SPAC merger presentation, Jan 18, 2024
Slide 1: Ultralow Frequency Transmitted Sound Imaging Investor Presentation
Ultralow Frequency Transmitted Sound Imaging INVESTOR PRESENTATION January 2024 1 Filed by GigCapital5, Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: QT Imaging,
Slide 2: Disclaimer
Disclaimer ABOUT THIS PRESENTATION This investor presentation (this “Presentation”) is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to the proposed business combination (the “Proposed Business Combination”) be
Slide 3: Disclaimer – Cont.
Copyright © 2024 QT Imaging, Inc. All Rights Reserved. Disclaimer – Cont. Industry and Market Data Industry and Market data used in this Presentation have been obtained from public sources and third-party industry publications. Such data has not been independently verified by QT Imaging or GigCapita
Slide 4: Disclaimer – Cont. Forward Looking Statements
Copyright © 2024 QT Imaging, Inc. All Rights Reserved. Disclaimer – Cont. Forward Looking Statements – Cont. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of the parties to the Prop
Slide 5: Disclaimer – Cont. Forward Looking Statements
Copyright © 2024 QT Imaging, Inc. All Rights Reserved. Disclaimer – Cont. Forward Looking Statements – Cont. If any of these risks, uncertainties or other factors materialize or QT Imaging’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward
Slide 6: Disclaimer – Cont. Trademark and Intellectual Property
Copyright © 2024 QT Imaging, Inc. All Rights Reserved. Disclaimer – Cont. Trademark And Intellectual Property QT Imaging and GigCapital5 own or have proprietary rights to various trademarks, service marks and trade names used in this Presentation that are important to their respective businesses, ma
Slide 7: Disclaimer – Cont. Additional Information and Where To Find It
Copyright © 2024 QT Imaging, Inc. All Rights Reserved. Disclaimer – Cont. Additional Information and Where To Find It In connection with the Proposed Business Combination, it is intended that GigCapital5 will prepare the GigCapital5 proxy statement/prospectus in a registration statement on Form S-4
Slide 8: GigCapital Leadership has a Proven History of Successful SPAC Transactions
GigCapital Leadership has a Proven History of Successful SPAC Transactions GigCapital5, Inc. (Nasdaq: GIA) is a publicly traded Special Purpose Acquisition Company (“SPAC”) GigCapital5’s IPO was completed in September 2021 Led by a proven management team of experienced entrepreneurs and executives D
Slide 9: GigCapital Recognizes QT Imaging's Potential to Transform Medical Imaging
GigCapital Recognizes QT Imaging’s Potential to Transform Medical Imaging Copyright © 2023 QT Imaging, Inc. All Rights Reserved. 2 QTI is a medical device company with imaging technology that has the potential to transform the industry QTI Scanner is the only imaging device to receive FDA clearance
Slide 10: Introduction to the QT Imaging Management Team
Introduction to the QT Imaging Management Team CEO & CHIEF MEDICAL OFFICER CHIEF PRODUCT OFFICER John Klock, MD Dr. Klock co-founded QT Imaging in 2011 and spearheaded the development and commercialization of the QT Scanner. Prior to QTI, he was involved in the founding of multiple disruptive medica
Slide 11: Our Mission
Our Mission Develop a safe, more accurate comprehensive imaging system, while increasing the speed and lowering the cost of medical imaging Develop an FDA-cleared, innovative imaging system capable of detecting masses in dense breasts Develop a safe, full-body imaging technology that can be at the p
Slide 12: Executive Summary
Executive Summary Low-cost, comprehensive, no radiation medical imaging solution yielding sub-millimeter, high-definition, image resolution: application in areas such as breast • infant body • orthopedics Commercial stage, FDA-cleared(1) breast scanner for dense breast imaging, with better sensitivi
Slide 13: QTI's Technology Has the Opportunity to Transform Several Large Markets
. New market opportunity given limitations of current imaging modalities for infants Commenced feasibility study Variety of image-guided procedures including biopsies, injections and cryoablation QTI’s Technology Has the Opportunity to Transform Several Large Markets Current Market FDA approved as s
Slide 14: Sales Agent Agreement signed with NXC Imaging marks a major milestone
Copyright © 2023 QT Imaging, Inc. All Rights Reserved. Sales Agent Agreement signed with NXC Imaging marks a major milestone for QT Imaging Accessing NXC Imaging's distribution channel in the US and the US territories, this agreement provides potential to accelerate the commercial roll-out of QTI’s
Slide 15: Investment Highlights
Investment Highlights Cutting-edge imaging technology with multiple potential applications creates a tremendous opportunity to transform the imaging market Experienced and Committed Executive Suite Industry-Transforming Imaging Technology Platform Recognized by Industry Incumbents Recent Changes to
Slide 16: Technology Overview
.@) imaging TECHNOLOGY OVERVIEW
Slide 17: Current Ultrasound Technologies Have Major Deficiencies
Current Ultrasound Technologies Have Major Deficiencies Clinically useful sensitivity and specificity Presence of comparative clinical trials Proven success in head-to-head trials against mammography for primary screening Ability for doubling times – can identify slow growing cancers and help preven
Slide 18: Why Does QTI Volography Have 40x the Resolution of The Best MRI?
Why Does QTI Volography Have 40x the Resolution of The Best MRI? More Data MRI QTI Volography (3D UT) volumetric planar QT duplication of data means: Higher Resolution Higher Detection Higher Signal to Noise Note: Voxel is a 3D version of a pixel 10 MRI image has 2mm gaps between each 2D collection
Slide 19: Resolution and Detectability: MRI vs QTI Volography
Volography (3D UT) with reflection mode Resolution is almost isotropic Sub-mm resolution Detectability 0.05 mm ~40x resolution of 3T MRI MRI resolution depends on acquisition time, B1 inhomogeneity, etc. Resolution and Detectability: MRI vs QTI Volography (3D UT) First time structures as small as th
Slide 20: Breast Health
.@) imaging BREAST HEALTH
Slide 21: QT Imaging's FDA-cleared Solution for Dense Breasts
Copyright © 2023 QT Imaging, Inc. All Rights Reserved. QT Imaging’s FDA-cleared Solution for Dense Breasts 50% of women between the ages of 40-74 in the US have dense breasts(1) MANY WOMEN HAVE DENSE BREASTS, WHICH MAMMOGRAMS ARE INEFFICIENT IN SCREENING FOR CANCER Dense BreastOther 50% 50% Mammogra
Slide 22: Dense Breast Imaging Study
CYSTS IMPLANT WITH MASS CANCER CLINICAL TRIALS: Dense Breast Imaging Study Confirmed DBT = 40% False-Negatives Copyright © 2023 QT Imaging, Inc. All Rights Reserved. Approximately 50% of women between the ages of 40-74 in the US have dense breasts(1), with traditional mammography missing 35.6-52.2%
Slide 23: Other Ultrasound Products Use B-mode Imaging for Dense Breast Screening
INVENIA ABUS ACUSON S2000 ABVS AWBUS SOFIA 3D DELPHINUS SOFTVUE QT BREAST SCANNER DESIGN TYPE Articulating Arm Articulating Arm Articulating Arm Guided Handheld Rotating Armature Water Bath Water Bath OUTPUT Stacked 2D Reflection Slices Stacked 2D Reflection Slices Stacked 2D Reflection Slices Stack
Slide 24: The Current Breast Imaging Paradigm Leads to Unnecessary Concern and Costs
35% 65% Do not follow guidelines Follow guidelines OVER 80% OF CALLBACK BIOPSIES ARE BENIGN(4) 98% OF RECALLS ARE AVOIDABLE Mammography. Center for Disease Control and Prevention Very Well Health | 13 Reasons for a Mammogram Callback | Larell Scardelli PubMed | False-Negative Rate of Combined Mammog
Slide 25: Current and Future Uses of QT Breast Scanner
Current and Future Uses of QT Breast Scanner Copyright © 2023 QT Imaging, Inc. All Rights Reserved. CURRENT APPLICATION FUTURE POTENTIAL APPLICATIONS Currently used in clinics for both primary and supplementary screening, upon MD or self-referral can be used for screening but cannot be marketed as a
Slide 26: QTI Offers Potential Capabilities for Screening, Diagnosis, and Monitoring
QTI Offers Potential Capabilities for Screening, Diagnosis, and Monitoring Complementary screening (Approved) Dense Breasts Intermediate to high-risk women Implants Primary screening for mammogram underserved patients (age <35) Young, high-risk women with predisposal to cancer or previous chest radi
Slide 27: The QT Scanner Delivers a Better Experience for Patients
The QT Scanner Delivers a Better Experience for Patients than Traditional Systems QT IMAGING MRI HANDHELD ULTRASOUND MAMMOGRAPHY Copyright © 2023 QT Imaging, Inc. All Rights Reserved. Image Quality Safety(1) Speed Cost Efficiency Patient Experience 21 The QTI Imaging Advantage ....OVER MAMMOGRAPHY I
Slide 28: Published Studies on Quantitative Transmission Ultrasound
Visual Grading Assessment of Quantitative Transmission Ultrasound Compared to Digital X-ray Mammography and Hand-held Ultrasound Anatomy-Correlated Breast Imaging and Visual Grading Analysis Using Quantitative Transmission Ultrasound QT can see more anatomy than mammography or handheld ultrasound Ac
Slide 29: Clinical Trials: Two Blinded Randomized Trials Completed and Published
CLINICAL TRIALS: Two Blinded Randomized Trials Completed and Published VS STUDY #1 FFDM STUDY #2 (Comparison to Digital Breast Tomosynthesis) Copyright © 2023 QT Imaging, Inc. All Rights Reserved. Study #1: An Exploratory Multi-reader, Multi-case Study Comparing Transmission Ultrasound to Mammograph
Slide 30: Clinical Adoption
.@) imaging CLINICAL ADOPTION
Slide 31: Key Milestones Have Been Achieved, with Additional Catalysts
Key Milestones Have Been Achieved, with Additional Catalysts to Drive Commercial Adoption and Increased Market Share Key Milestones Achieved for Commercial Adoption Four placements in North America Three placements internationally Generate and publish clinical data Develop market advocates Signed Sa
Slide 32: Pricing Structures Allow Providers Flexibility in Using the QT Scanner
Traditional Upfront Purchase MSaaS (Medical Scan as a Service)/Per Click Model Turnkey Model (includes scan interpretation) * all require annual maintenance and custom disposables Pricing Structures Allow Providers Flexibility in Using the QT Scanner INITIAL TARGET MARKETS Community Cancer Centers A
Slide 33: Reimbursement Will Be Driven by the Value and Savings Provided to Patients
Reimbursement Will Be Driven by the Value and Savings Provided to Patients Copyright © 2023 QT Imaging, Inc. All Rights Reserved. CURRENT Existing CPT codes, non-specific to QTI technology: Unilateral or Bilateral breast ultrasound (76641 or 76642) 3D rendering (76377) Other ultrasound procedures (7
Slide 34: Open Angle Scanner
.@) imaging OPEN ANGLE SCANNER
Slide 35: Developing an Open Angle Scanner Will Expand the Technology to New Markets
Developing an Open Angle Scanner Will Expand the Technology to New Markets … PROVIDING SIGNIFICANT POTENTIAL TO ACCESS NEW MARKETS AND APPLICATIONS The Open Angle Scanner uses an open, partial angle configuration which reduces the viewing field from 3600 to 3250 and provides additional capabilities
Slide 36: The Infrastructure is in Place to Allow for the Rollout of the Next Generation Scanner
The Infrastructure is in Place to Allow for the Rollout of the Next Generation Scanner Prototype Design and Build MAJOR MILESTONE NEXT GENERATION OPEN ANGLE SCANNER 18 MONTHS Copyright © 2023 QT Imaging, Inc. All Rights Reserved. 24 Key Infrastructure in Place for Development Underlying ultra-low fr
Slide 37: Open Angle Scanner Development Pathway and Corresponding Catalysts
Open Angle Scanner Development Pathway and Corresponding Catalysts 510(k) Ortho Software Development Infant Software Development Image-Guided Procedure Software Development Prototype Design & Build (First Clinical Trials) Proof of Concept Open Angle Hardware Development Rollout Submitted w/Hardware
Slide 38: Risk Factors
Copyright © 2024 QT Imaging, Inc. All Rights Reserved. Risk Factors All references to “QT Imaging,” “Company,” “we,” “us” or “our” refer to the business of QT Imaging, Inc. The risks presented below are certain of the general risks of the Company, GigCapital5, Inc (“SPAC”), and the proposed transact
Slide 39: Risk Factors – Cont. Development Stage Technology Risks
Copyright © 2024 QT Imaging, Inc. All Rights Reserved. Risk Factors – Cont. Development Stage Technology Risks The market for the Company’s medical scanner is subject to technological change. The success of the Company depends on the timely perception of new trends, developments and customer needs,
Slide 40: Risk Factors – Cont. Intellectual Property Risks
Copyright © 2024 QT Imaging, Inc. All Rights Reserved. Risk Factors – Cont. Intellectual Property Risks Although the Company has been granted several patents, no assurances can be given that the scope of any patent protection will exclude competitors or provide competitive advantages to the Company,
Slide 41: Risk Factors – Cont. General Business Risks
Copyright © 2024 QT Imaging, Inc. All Rights Reserved. Risk Factors – Cont. General Business Risks Downturns or volatility in general economic conditions could have a material adverse effect on the Company’s business, financial condition, results of operations and liquidity. The Company's competitiv
Slide 42: Risk Factors – Cont. Risks Related to the Business Combination
Copyright © 2024 QT Imaging, Inc. All Rights Reserved. Risk Factors – Cont. Risks Related to the Business Combination The Proposed Business Combination may disrupt current plans and operations of the Company. If the Proposed Business Combination’s benefits do not meet expectations of investor or sec
Slide 43: Thank You!
.@) imaging THANK YOU!